Century Therapeutics, Inc. Comprehensive Income
Century Therapeutics, Inc. (IPSC) reported Comprehensive Income of -$34.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$34.66M.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$22.26M, a 129.08% decline year-over-year.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$19.20M.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$34.44M.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$9.87M.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$126.35M.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$134.10M.
- Century Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$132.74M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.66M 10-Q · filed 2026-08-12 | -$56.92M 10-Q · filed 2026-08-12 | -$76.12M derived: sum of 3 quarters · filed 2026-08-12 | -$110.56M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$22.26M 10-Q · filed 2026-05-13 | -$41.47M derived: sum of 2 quarters · filed 2026-05-13 | -$75.91M derived: sum of 3 quarters · filed 2026-05-13 | -$108.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$19.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$53.65M derived: sum of 2 quarters · filed 2026-03-12 | -$86.41M derived: sum of 3 quarters · filed 2026-08-12 | -$9.87M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$34.44M 10-Q · filed 2025-11-13 | -$67.20M derived: sum of 2 quarters · filed 2026-08-12 | $9.33M 10-Q · filed 2025-11-13 | -$27.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$32.76M 10-Q · filed 2026-08-12 | $43.78M 10-Q · filed 2026-08-12 | $7.27M derived: sum of 3 quarters · filed 2026-08-12 | -$22.89M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $76.54M 10-Q · filed 2026-05-13 | $40.03M derived: sum of 2 quarters · filed 2026-05-13 | $9.88M derived: sum of 3 quarters · filed 2026-05-13 | -$21.40M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$36.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$66.67M derived: sum of 2 quarters · filed 2026-03-12 | -$97.94M derived: sum of 3 quarters · filed 2026-03-12 | -$126.35M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$30.16M 10-Q · filed 2025-11-13 | -$61.43M derived: sum of 2 quarters · filed 2025-11-13 | -$89.84M 10-Q · filed 2025-11-13 | -$127.83M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$31.27M 10-Q · filed 2025-08-14 | -$59.69M 10-Q · filed 2025-08-14 | -$97.67M derived: sum of 3 quarters · filed 2025-08-14 | -$130.49M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$28.41M 10-Q · filed 2025-05-15 | -$66.39M derived: sum of 2 quarters · filed 2025-05-15 | -$99.21M derived: sum of 3 quarters · filed 2025-05-15 | -$132.44M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$37.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$70.80M derived: sum of 2 quarters · filed 2025-03-19 | -$104.02M derived: sum of 3 quarters · filed 2025-03-19 | -$134.10M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$32.82M 10-Q · filed 2024-11-05 | -$66.04M derived: sum of 2 quarters · filed 2024-11-05 | -$96.12M 10-Q · filed 2024-11-05 | -$126.66M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$33.22M 10-Q · filed 2024-08-08 | -$63.30M 10-Q · filed 2024-08-08 | -$93.84M derived: sum of 3 quarters · filed 2024-08-08 | -$124.76M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$30.08M 10-Q · filed 2024-05-09 | -$60.62M derived: sum of 2 quarters · filed 2024-05-09 | -$91.54M derived: sum of 3 quarters · filed 2024-05-09 | -$123.32M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$30.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$61.46M derived: sum of 2 quarters · filed 2024-03-14 | -$93.24M derived: sum of 3 quarters · filed 2024-03-14 | -$132.74M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$30.92M 10-Q · filed 2023-11-09 | -$62.70M derived: sum of 2 quarters · filed 2023-11-09 | -$102.20M 10-Q · filed 2023-11-09 | -$130.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$31.78M 10-Q · filed 2023-08-09 | -$71.28M 10-Q · filed 2023-08-09 | -$100.07M derived: sum of 3 quarters · filed 2023-08-09 | -$126.14M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$39.51M 10-Q · filed 2023-05-11 | -$68.29M derived: sum of 2 quarters · filed 2023-05-11 | -$94.36M derived: sum of 3 quarters · filed 2023-05-11 | -$117.61M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$28.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$54.85M derived: sum of 2 quarters · filed 2023-03-16 | -$78.10M derived: sum of 3 quarters · filed 2023-03-16 | -$96.47M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$26.07M 10-Q · filed 2022-11-10 | -$49.32M derived: sum of 2 quarters · filed 2022-11-10 | -$67.69M 10-Q · filed 2022-11-10 | -$83.26M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$23.25M 10-Q · filed 2022-08-11 | -$41.62M 10-Q · filed 2022-08-11 | -$57.20M derived: sum of 3 quarters · filed 2022-08-11 | -$70.35M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$18.37M 10-Q · filed 2022-05-16 | -$33.95M derived: sum of 2 quarters · filed 2022-05-16 | -$47.10M derived: sum of 3 quarters · filed 2022-05-16 | -$62.30M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$28.73M derived: sum of 2 quarters · filed 2022-03-17 | -$43.93M derived: sum of 3 quarters · filed 2022-03-17 | -$53.58M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$13.15M 10-Q · filed 2021-11-10 | -$28.36M derived: sum of 2 quarters · filed 2021-11-10 | -$38.00M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$15.20M 10-Q · filed 2021-08-12 | -$24.85M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |